• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CU6
Click for more information
0.57% $8.65

CLARITY PHARMACEUTICALS LTD - Charts / Financials

Market Cap $2.734B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 27/09/2024 (20 minute delay) ?
Day
Open $8.65   Day High $8.79   Day Low $8.40
Daily Volume 1676182
Bids   Sellers
Number Price Volume   Number Price Volume
1 $8.60 59   1 $8.65 21036

Data source: Refinitiv

(20min delay)
Last
$8.65 		Change
-0.050(0.57%) 		Mkt cap ! $2.734B
Open High Low Value Volume
$8.65 $8.79 $8.40 $14.40M 1.676M

Buyers (Bids)

No. Vol. Price($)
1 59 $8.60
 

Sellers (Offers)

Price($) Vol. No.
$8.65 21036 1
View Market Depth
Last trade - 16.10pm 27/09/2024 (20 minute delay) ?
Last
$8.64 		  Change
-0.050 ( 0.59 %)
Open High Low Volume
$8.64 $8.78 $8.41 192030
Last updated 15.59pm 27/09/2024 ?

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders Estrella has become the first foreign entity to win mining acreage in Timor-Leste under that country's new mining laws enacted in 2021.
The market's shrugged at China's stimulus measures all year. Why is this one different? If you've been following the Chinese economy this year, you'd know that the country has been trying to stimulate all year.
The winners & losers on market if negative gearing were gone Removing negative gearing would likely cause a seismic shift in investor behaviour. If that advantage were taken away, more investors might start eyeing the stock market...
ACCC seeks Olam divestments before it can buy Namoi Cotton Australia's market regulator the ACCC has expressed further concerns about the potential takeover of Namoi Cotton by Olam Agri.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.